These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

200 related articles for article (PubMed ID: 35361730)

  • 41. Tumour-draining axillary lymph nodes in patients with large and locally advanced breast cancers undergoing neoadjuvant chemotherapy (NAC): the crucial contribution of immune cells (effector, regulatory) and cytokines (Th1, Th2) to immune-mediated tumour cell death induced by NAC.
    Kaewkangsadan V; Verma C; Eremin JM; Cowley G; Ilyas M; Eremin O
    BMC Cancer; 2018 Feb; 18(1):123. PubMed ID: 29390966
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Characterization of the Immune Microenvironment in Inflammatory Breast Cancer Using Multiplex Immunofluorescence.
    Badr NM; McMurray JL; Danial I; Hayward S; Asaad NY; Abd El-Wahed MM; Abdou AG; Serag El-Dien MM; Sharma N; Horimoto Y; Sircar T; Vidya R; Hoar F; Rea D; Jones JL; Stevens A; Spooner D; Merard R; Lewis P; Hunter KJ; Berditchevski F; Shaaban AM
    Pathobiology; 2023; 90(1):31-43. PubMed ID: 35705026
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Interaction between Molecular Subtypes and Stromal Immune Infiltration before and after Treatment in Breast Cancer Patients Treated with Neoadjuvant Chemotherapy.
    Hamy AS; Bonsang-Kitzis H; De Croze D; Laas E; Darrigues L; Topciu L; Menet E; Vincent-Salomon A; Lerebours F; Pierga JY; Brain E; Feron JG; Benchimol G; Lam GT; Laé M; Reyal F
    Clin Cancer Res; 2019 Nov; 25(22):6731-6741. PubMed ID: 31515462
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Tumor Microenvironment Status Predicts the Efficacy of Postoperative Chemotherapy or Radiochemotherapy in Resected Gastric Cancer.
    Duan R; Li X; Zeng D; Chen X; Shen B; Zhu D; Zhu L; Yu Y; Wang D
    Front Immunol; 2020; 11():609337. PubMed ID: 33569057
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Changes in the immune landscape of TNBC after neoadjuvant chemotherapy: correlation with relapse.
    Moamin MR; Allen R; Woods SL; Brown JE; Nunns H; Juncker-Jensen A; Lewis CE
    Front Immunol; 2023; 14():1291643. PubMed ID: 38090569
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Pre-treatment peripheral blood immunophenotyping and response to neoadjuvant chemotherapy in operable breast cancer.
    Leon-Ferre RA; Whitaker KR; Suman VJ; Hoskin T; Giridhar KV; Moore RM; Al-Jarrad A; McLaughlin SA; Northfelt DW; Hunt KN; Conners AL; Moyer A; Carter JM; Kalari K; Weinshilboum R; Wang L; Ingle JN; Knutson KL; Ansell SM; Boughey JC; Goetz MP; Villasboas JC
    Breast Cancer Res; 2024 Jun; 26(1):97. PubMed ID: 38858721
    [TBL] [Abstract][Full Text] [Related]  

  • 47. GGT5: a potential immunotherapy response inhibitor in gastric cancer by modulating GSH metabolism and sustaining memory CD8+ T cell infiltration.
    Zhao W; Liang Z; Yao Y; Ge Y; An G; Duan L; Yao J
    Cancer Immunol Immunother; 2024 May; 73(7):131. PubMed ID: 38748299
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Regulatory T cells and M2 macrophages present diverse prognostic value in gastric cancer patients with different clinicopathologic characteristics and chemotherapy strategies.
    Liu X; Xu D; Huang C; Guo Y; Wang S; Zhu C; Xu J; Zhang Z; Shen Y; Zhao W; Zhao G
    J Transl Med; 2019 Jun; 17(1):192. PubMed ID: 31174544
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Tumor-infiltrating immune cell profiles and changes associate with additional trastuzumab in preoperative chemotherapy for patients with HER2-positive gastric cancer.
    Chen C; Han J; He Q; Yao Q; Wang X; Peng Z; Sun Y; Ji J; Xing X
    Br J Cancer; 2024 Nov; 131(9):1463-1472. PubMed ID: 39313575
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Residual cancer burden index and tumor-infiltrating lymphocyte subtypes in triple-negative breast cancer after neoadjuvant chemotherapy.
    Pinard C; Debled M; Ben Rejeb H; Velasco V; Tunon de Lara C; Hoppe S; Richard E; Brouste V; Bonnefoi H; MacGrogan G
    Breast Cancer Res Treat; 2020 Jan; 179(1):11-23. PubMed ID: 31529299
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Tumor-infiltrating CD8+ and FOXP3+ lymphocytes before and after neoadjuvant chemotherapy in cervical cancer.
    Liang Y; Lü W; Zhang X; Lü B
    Diagn Pathol; 2018 Nov; 13(1):93. PubMed ID: 30474571
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Tumor-infiltrating M2 macrophage in pretreatment biopsy sample predicts response to chemotherapy and survival in esophageal cancer.
    Yamamoto K; Makino T; Sato E; Noma T; Urakawa S; Takeoka T; Yamashita K; Saito T; Tanaka K; Takahashi T; Kurokawa Y; Yamasaki M; Nakajima K; Mori M; Doki Y; Wada H
    Cancer Sci; 2020 Apr; 111(4):1103-1112. PubMed ID: 31981293
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Neoadjuvant Chemotherapy Increases Cytotoxic T Cell, Tissue Resident Memory T Cell, and B Cell Infiltration in Resectable NSCLC.
    Gaudreau PO; Negrao MV; Mitchell KG; Reuben A; Corsini EM; Li J; Karpinets TV; Wang Q; Diao L; Wang J; Federico L; Parra-Cuentas ER; Khairullah R; Behrens C; Correa AM; Gomez D; Little L; Gumbs C; Kadara HN; Fujimoto J; McGrail DJ; Vaporciyan AA; Swisher SG; Walsh G; Antonoff MB; Weissferdt A; Tran H; Roarty E; Haymaker C; Bernatchez C; Zhang J; Futreal PA; Wistuba II; Cascone T; Heymach JV; Sepesi B; Zhang J; Gibbons DL
    J Thorac Oncol; 2021 Jan; 16(1):127-139. PubMed ID: 33096269
    [TBL] [Abstract][Full Text] [Related]  

  • 54. A risk signature with inflammatory and immune cells infiltration predicts survival and efficiency of chemotherapy in gastric cancer.
    Li S; Sun S; Sun H; Ma P; Zhang J; Cao Y; Liu C; Zhang X; Wang W; Li Z; Ma Y; Xue Y; Zhao Y
    Int Immunopharmacol; 2021 Jul; 96():107589. PubMed ID: 34162126
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Tumor mutation burden as a biomarker in resected gastric cancer via its association with immune infiltration and hypoxia.
    Wang D; Wang N; Li X; Chen X; Shen B; Zhu D; Zhu L; Xu Y; Yu Y; Shu Y
    Gastric Cancer; 2021 Jul; 24(4):823-834. PubMed ID: 33687617
    [TBL] [Abstract][Full Text] [Related]  

  • 56. An Immunoscore Using PD-L1, CD68, and Tumor-infiltrating Lymphocytes (TILs) to Predict Response to Neoadjuvant Chemotherapy in Invasive Breast Cancer.
    McLemore LE; Janakiram M; Albanese J; Shapiro N; Lo Y; Zang X; Fineberg S
    Appl Immunohistochem Mol Morphol; 2018 Oct; 26(9):611-619. PubMed ID: 28422766
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Early Stage HER2-Positive Breast Cancers Not Achieving a pCR From Neoadjuvant Trastuzumab- or Pertuzumab-Based Regimens Have an Immunosuppressive Phenotype.
    Force J; Howie LJ; Abbott SE; Bentley R; Marcom PK; Kimmick G; Westbrook K; Sammons SL; Parks M; Topping DL; Emerson R; Broadwater G; Hyslop T; Blackwell KL; Nair SK
    Clin Breast Cancer; 2018 Oct; 18(5):410-417. PubMed ID: 29615305
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Immune cell analyses of the tumor microenvironment in prostate cancer highlight infiltrating regulatory T cells and macrophages as adverse prognostic factors.
    Andersen LB; Nørgaard M; Rasmussen M; Fredsøe J; Borre M; Ulhøi BP; Sørensen KD
    J Pathol; 2021 Oct; 255(2):155-165. PubMed ID: 34255349
    [TBL] [Abstract][Full Text] [Related]  

  • 59. The association between the tumor immune microenvironments and clinical outcome in low-grade, early-stage endometrial cancer patients.
    López-Janeiro Á; Villalba-Esparza M; Brizzi ME; Jiménez-Sánchez D; Ruz-Caracuel I; Kadioglu E; Masetto I; Goubert V; Garcia-Ros D; Melero I; Peláez-García A; Hardisson D; de Andrea CE
    J Pathol; 2022 Dec; 258(4):426-436. PubMed ID: 36169332
    [TBL] [Abstract][Full Text] [Related]  

  • 60. CD226 identifies functional CD8
    Huang H; Huang Z; Ge J; Yang J; Chen J; Xu B; Wu S; Zheng X; Chen L; Zhang X; Jiang J
    Front Immunol; 2023; 14():1150803. PubMed ID: 37056782
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.